SENTI-202
Near Add Your Location
Accepting patients
SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
- Natural Killer Cells (Allogeneic)
- CD33
- FLT3 Inhibitor
- Phase 1
Showing 1-1 of 1